Tropomyosin receptor kinase inhibitors: A patent update 2009-2013

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 7, 2014, Pages 731-744

  McCarthy, Clive ^a   Walker, Edward ^a  

^a EVOTEC UK LTD   (United Kingdom)

Author keywords

Oncology; Pain; Pruritis; Respiratory disease; Tropomyosin receptor kinases; Tropomyosin related kinase; Tropomyosin related kinase A inhibitors

Indexed keywords

CARBOXYLIC ACID; CE 245677; CRIZOTINIB; CT 327; EX 429; GW 2580; IMIDAZOPYRIDINE DERIVATIVE; NEUROTROPHIN; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLOPYRIDINE; PYRIDINE DERIVATIVE; TANEZUMAB; THIADIAZOLE DERIVATIVE; TROPOMYOSIN; TROPOMYOSIN RECEPTOR KINASE INHIBITOR; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TROPOMYOSIN KINASE; TROPOMYOSIN-RELATED KINASE-B, HUMAN;

ALZHEIMER DISEASE; ATOPIC DERMATITIS; CANCER PATIENT; CLINICAL EVALUATION; DRUG CONFORMATION; DRUG INDUSTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE FUSION; HUMAN; LUNG CANCER; MOLECULE; NEOPLASM; NONHUMAN; OSTEOARTHRITIS; PAIN; PATENT; PHARMACODYNAMICS; PRURITUS; PSORIASIS; RESPIRATORY TRACT DISEASE; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS;

ANIMALS; HUMANS; MEMBRANE GLYCOPROTEINS; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-TYROSINE KINASES; TROPOMYOSIN;

EID: 84903143082     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.910195     Document Type: Review

References (81)

1. Cohen S, Levi-Montalcini R, Hamburger V. A nerve growthstimulating factor isolated from sarcomas 37 and 180. Proc Natl Acad Sci USA 1954;40:1014-18
2. Klein R, Nanduri V, Jing SA, et al. Cloning and expression of a novel neurotrophin, NT-7, from carp. Cell 1991;66:395-403
3. Gotz R, Koster R, Winkler C, Raulf F. Neurotrophin-6 is a new member of the nerve growth factor family. Nature 1994;372:266-9 (Pubitemid 24352448)
4. Ip NY, Ibanez CF, Nye SH, McClain J. Mammalian neurotrophin-4: structure, chromosomal localisation, tissue distribution and receptor specificity. Proc Natl Acad Sci USA 1992;89:3060-4
5. Lamballe F, Klein R, Barbacid M. TrkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell 1991;66:967-79 (Pubitemid 121001730)
6. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-70 (Pubitemid 38579482)
7. Thiele CJ, Li Z, McKee AE. On Trk-The TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res 2009;15:5962-7
8. Papatsoris AG, Liolitsa D, Deliveliotis C. Manipulation of the nerve growth factor network in prostate cancer. Expert Opin Investig Drugs 2007;16:303-9 (Pubitemid 46394855)
9. Weeraratna AT, Arnold JT, George DJ. Rational basis for Trk inhibition therapy for prostate cancer. Prostate 2000;45:140-8
10. Hondermarck H. Neurotrophins and their receptors in breast cancer. Cytokine Growth Factor Rev 2012;23:357-65
11. Sclabas GM, Fujioka S, Schmidt C. Overexpression of tropomyosin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res 2005;11:440-9 (Pubitemid 40116865)
12. Rubin BP, Chen CJ, Morgan TW, et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol 1998;153:1451-8 (Pubitemid 28509901)
13. Euhus DM, Timmons CF, Tomlinson GE. ETV6-NTRK3-Trk-ing the primary event in human secretory breast cancer. Cancer Cell 2002;2:347-8 (Pubitemid 41039098)
14. Pierotti MA, Greco A. Oncogenic rearrangements of the NTRK1/NGF receptor. Cancer Lett 2006;232:90-8 (Pubitemid 43053936)
15. Greco A, Miranda C, Pierotti MA. Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol 2010;321:44-9
16. Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 2013;19:1469-72
17. Frampton JE. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs 2013;73:2031-51
18. Indo Y, Tsuruta M, Hayashida Y. Mutations in the TrkA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet 1996;13:485-8 (Pubitemid 26256627)
19. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from Osteoarthritis of the knee. N Engl J Med 2010;363:1521-31
20. Brown MT, Murphy FT, Radin DM, et al. Tanezumab reduces Osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum 2013;65:1795-803
21. Ghilardi JR, Freeman KT, Jimenez-Andrade JM, et al. Administration of a tropomyosin receptor kinase inhibitor attenuates sarcomainduced nerve sprouting, neuroma formation and bone cancer pain. Mol Pain 2010;6:87-100
22. Skerratt S. The discovery and optimisation of a series of potent, selective and CNS restricted pan-Trk ligands for pain. 2013
23. Andrews SW. Allosteric Small Molecule Inhibitors of the NGF/TrkA Pathway. A New Approach to Treating Inflammatory Pain. Array Website,2012. Available from: http://www.arraybiopharma.com/-documents/Publication/PubAttachment587.pdf [Last accessed 22 January 2014]
24. Kim JS, Kang JY, Ha JH, et al. Expression of nerve growth factor and matrix metallopeptidase-9/tissue inhibitor of metalloproteinase-1 in asthmatic patients. J Asthma 2013;50:712-17
25. Yang YG, Tian WM, Zhang H. Nerve growth factor exacerbates allergic lung inflammation and airway remodeling in a rat model of chronic asthma. Exp Ther Med 2013;6:1251-8
26. Creabilis Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327. PR Newswire. 2013. Available from: http://www.prnewswire.com/newsreleases/creabilis-announces-headlineresults-of- its-phase-2b-trial-of-topicaltrka-kinase-inhibitor-ct327-206885021. html [Last Accessed 22 January 2014]
27. Weinkauf C, Pereiraperrin M. Trypanosoma cruzi promotes neuronal and glial cell survival through the neurotrophic receptor TrkC. Infect Immun 2009;77:1368-75
28. Weinkauf C, Salvador R, Pereiraperrin M. Neurotrophin receptor TrkC is an entry receptor for Trypanosoma cruzi in neural, glial, and epithelial cells. Infect Immun 2011;79:4081-7
29. Albaugh P, Fan Y, Mi Y, Sun F. Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models. ACS Med Chem Lett 2012;3:140-5
30. Pargellis C, Tong L, Churchill L. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002;9:268-72 (Pubitemid 34289898)
31. Wang T, Lamb ML, Block MH, et al. Discovery of Disubstituted Imidazo[4,5-b]pyridines and purines as potent TrkA inhibitors. ACS Med Chem Lett 2012;3:705-9
32. Wang T, Lamb ML, Scott DA, et al. Identification of 4- Aminopyrazolylpyrimidines as potent inhibitors of Trk kinases. J Med Chem 2008;51:4672-84
33. Bertrand T, Kothe M, Liu J. The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition. J Mol Biol 2012;423:439-53
34. Wang T, Yu D, Lamb ML. Trk kinase inhibitors as new treatments for cancer and pain. Expert Opin Ther Pat 2009;19:305-19
35. Andrews SW, Haas J, Jiang Y, Zhang G. Substituted imidazo[1,2-b] pyridazine compounds as Trk kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2010033941; 2010
36. Haas J, Andrews SW, Jiang Y, Zhang G. Substituted pyrazolo[1,5-a] pyrimidine compounds as Trk kinase inhibitors and their preparation and use in the treatment of diseases. WO2010048314; 2010
37. Allen S, Andrews SS, Condroski KR, et al. Preparation of substituted pyrazolo [1,5-a]pyrimidine compounds as selective Trk kinase inhibitors. WO2011006074; 2011
38. Blaney J, Gibbons PA, Hanan E, et al. Pyrazolopyrimidines as JAK inhibitor compounds and their preparation. WO2010051549; 2010
39. Andrews SW, Condroski KR, Haas J, et al. Preparation of macrocyclic compounds as trk kinase inhibitors. WO2011146336; 2011
40. Allen S, Andrews SW, Blake JF, et al. Pyrrolidinylurea and pyrrolidinylthiourea compds. as TrkA kinase inhibitors and their preparation. WO2012158413; 2012
41. Marx MA, La Greca SD, Chen J, et al. Preparation of pyrrolopyrimidine derivatives useful in cancer treatment. WO2005116035; 2005
42. Chen P, Zhao Y, Fink BE, Kim S-H. Preparation of 4-aminopyrrolotriazines as tropomyosin related kinase inhibitors for the treatment of proliferative diseases. US7514435B2; 2009
43. John V, Zhang Q, Bredesen DE. TrkA as a target for inhibiting APP cleavage and/or progression of Alzheimer's disease. WO2013026021; 2013
44. Galvan V, Gorostiza OF, Banwait S, et al. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci USA 2006;103:7130-5
45. Katz J, Jewell J, Jung J, et al. Preparation of pyrazolopyridines and imidazopyridines as inhibitors of the kinase PDK1 useful for the treatment of myeloproliferative disorders or cancer. WO2010017047; 2010
46. Green A, Li Y, Stachel S. Preparation of pyridotriazole and benztriazole compds. as TrkA kinase inhibitors. WO2012125667; 2012
47. Green A, Li Y, Stachel S. TrkA kinase inhibitors, compositions and methods of use. WO2012125668; 2012
48. Hanney B, Manley P, Rudd MT, et al. Preparation of substituted pyrrolopyrazines and indoles as TrkA kinase inhibitors. WO2013009582; 2013
49. Stachel SJ, Egbertson M, Brnardic E, et al. Trka kinase inhibitors, compositions and methods thereof. WO2013176970; 2013
50. Scaburri A, Pacciarini MA, Ciomei M, et al. Use of a kinase inhibitor for the treatment of thymoma. WO2010106028; 2010
51. Albaugh PA, Choi H-S, Chopiuk G, et al. Preparation of imidazopyridazines and similar compounds as therapeutic kinase inhibitors. WO2009140128; 2009
52. Warmuth M, Kim S, Gu XJ. Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol 2007;19:55-60 (Pubitemid 44885601)
53. Fan Y, Loren J, Molteni V, et al. Preparation of imidazopyridazine derivatives for use as TRK inhibitors. WO2012034091; 2012
54. Harbeson SL, Tung RD. Deuterium in drug discovery and development. Annu Rep Med Chem 2011;46:403-17
55. Loren J, Molteni V, Fan Y, et al. Preparation of pyrazolopyrimidine derivatives for use as TRK inhibitors. WO2012034095; 2012
56. Molteni V, Fan Y, Loren J, et al. Pyrazolopyridine derivatives as TRK kinase inhibitors and their preparation and use for the treatment of TRK kinase-mediated diseases. WO2012116217; 2012
57. Takeuchi J, Ikura M, Higashino M, et al. Preparation of thiazole-containing urea derivatives as tropomyosin receptor kinase (Trk kinase) inhibitors. WO2013161919; 2013
58. Andrews MD, Bagal SK, Gibson KR, et al. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of tropomyosinrelated kinases and their preparation and use in the treatment of pain. WO2012137089; 2012
59. Sasmal PK, Ahmed S, Prabhu G, et al. Preparation of substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors. WO2013088257; 2013
60. Sasmal PK, Ahmed S, Tehim A, et al. Preparation of substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors. WO2013088256; 2013
61. Wilcoxen KM. Modulating certain tyrosine kinases. WO2013074518; 2013
62. Bode CM, Cheng AC, Choquette D, et al. Preparation of azabenzimidazole derivatives and analogs for use as anaplastic lymphoma kinase inhibitors. WO2012018668; 2012
63. Lewis RT, Bode CM, Choquette DM, Potashman M. The discovery and optimization of a novel class of potent, selective, and orally bioavailable Anaplastic Lymphoma Kinase (ALK) inhibitors with potential utility for the treatment of cancer. J Med Chem 2012;55:6523-40
64. Wu JJ-Q, Wang L. Preparation of and therapeutic compositions containing heterocyclic protein receptor tyrosine kinase inhibitors. WO2010077680; 2010
65. Scott LJ. Tofacitinib: a Review of its Use in Adult Patients with Rheumatoid Arthritis. Drugs 2013;73:857-74
66. Salama AKS, Kim KB. (GSK1120212) in the treatment of melanoma. Expert Opin Pharmacother 2013;14:619-27
67. Jang S, Atkins MB. Treatment of BRAF-mutant melanoma: the role of Vemurafenib and other therapies. Clin Pharmacol Ther 2014;95:24-31
68. Medina T, Amaria M.N, Jimeno A. Dabrafenib in the treatment of advanced melanoma. Drugs Today (Barc) 2013;49:377-85
69. Narayanan V, Pollyea DA, Gutman JA, Jimeno A. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Drugs Today (Barc) 2013;49:261-9
70. Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 2007;18:3-10
71. Demetri GD, Reicchardt P, Kang YK, Blay JY. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet 2013;381:295-302
72. Morphy R. Selectively nonselective kinase inhibition: striking the right balance. J Med Chem 2010;53:1413-37
73. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669-76 (Pubitemid 38596280)
74. Santos FPS, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or postpolycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010;115:1131-6
75. Shabbir M SR. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin Investig Drugs 2010;19:427-36
76. Boss DS, Beijnen JH, Schellens JHM. Clinical experience with Aurora kinase inhibitors: a review. Oncologist 2009;14:780-93
77. Logan TF. Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer. Curr Oncol Rep 2013;15:83-90
78. Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918. NIH clinical trial notification. 2010. Available from: http://clinicaltrials. gov/show/NCT00733031 [Last accessed 21 January 2014]
79. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 2003;72:609-42 (Pubitemid 36930455)
80. Gibbons DL, Pricl S, Kantarjian H, Cortes J. The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer 2012;118:293-9
81. Bikker JA, Brooijmans N, Wissner A, Mansour TS. Kinase domain mutations in cancer: implications for small molecule drug design strategies. J Med Chem 2009;52:1493-509